Norwegian cell therapy developer Zelluna reported a second-quarter operating loss of NOK 19.7 million as it advanced its ZIMA-101 cancer treatment trial, despite raising NOK 58.2 million through a private placement and retail offering.
The company’s operating expenses totaled NOK 19.90 million in the quarter, while it received a NOK 16 million grant to support clinical operations and the ongoing study. Zelluna also activated a second clinical site for the Phase 1 trial of ZIMA-101, with patient recruitment now underway at two locations following the addition of The Royal Marsden.
The firm dosed its first patient in the study during the quarter, with initial safety data indicating favorable results. Zelluna is concurrently working to expand its manufacturing capabilities to support the development of its TCR-NK platform, which underpins the ZIMA-101 program.
Zelluna’s current cash position is projected to fund operations through the third quarter of 2027, providing a financial runway as the company advances its clinical and manufacturing initiatives.
